• 1. Evolutionary approaches in protein engineering towards biomaterial construction
  Brindha J.,Balamurali M. M.,Kaushik Chanda RSC Adv., 2019,9, 34720-34734
• 2. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 3. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 4. Fe3O4/FeS2 heterostructures enable efficient oxygen evolution reaction?
  Xingqun Zheng,Lele Song,Xin Feng,Li Li,Zidong Wei J. Mater. Chem. A, 2020,8, 14145-14151
• 5. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Sesquiterpenoids Sesquiterpenoids
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Sesquiterpenoids
• Sesquiterpenoids

H-Cadina-4,11-Diene: A Comprehensive Overview

H-Cadina-4,11-diene, also known by its CAS registry number 92692-39-2, is a terpenoid compound that has garnered significant attention in the field of biomedicine due to its diverse biological activities. This naturally occurring compound belongs to the cadinaane family of sesquiterpenes, which are known for their complex structures and potent bioactive properties.

The structure of H-cadina-4,11-diene is characterized by a unique arrangement of beta, alpha, and gamma hydroxyl groups, along with conjugated double bonds that contribute to its antioxidant and anti-inflammatory potential. These structural features make it a promising candidate for drug development, particularly in the treatment of chronic diseases such as cancer, diabetes, and neurodegenerative disorders.

Recent studies have highlighted the compound's ability to modulate cell signaling pathways, including the MAPK and PI3K/AKT pathways, which are often dysregulated in cancer cells. This modulation suggests that H-cadina-4,11-diene may have anticancer properties, potentially offering a novel therapeutic approach for various malignancies.

Furthermore, research into the neuroprotective effects of this compound has shown promising results in preclinical models of Alzheimer's disease. By inhibiting beta-amyloid aggregation and reducing oxidative stress, H-cadina-4,11-diene demonstrates potential as a dementia treatment. These findings underscore the importance of further investigating its mechanisms of action in neural systems.

Another area of interest is the compound's role in inflammation regulation. Through interaction with COX-2 and iNOS enzymes, H-cadina-4,11-diene exhibits anti-inflammatory activity, which could be harnessed for treating inflammatory bowel diseases or arthritis. This dual action on both inflammation and cell proliferation makes it a versatile candidate for multifunctional drugs.

Preclinical trials have also explored the toxicological profile of H-cadina-4,11-diene, revealing minimal adverse effects at therapeutic doses. This safety profile, combined with its potent bioactivities, positions it as a lead compound for drug development in several therapeutic areas.

Finally, ongoing research is focusing on optimizing the bioavailability and pharmacokinetics of H-cadina-4,11-diene to enhance its efficacy. By employing advanced drug delivery systems, scientists aim to maximize the therapeutic potential of this compound while minimizing systemic side effects.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)